PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Van de Werf, Frans
TI  - TECOS Finds Sitagliptin Does Not Increase Heart Failure Risk
DP  - 2015 Nov 21
TA  - MD Conference Express
PG  - 15--16
VI  - 15
IP  - 28
4099  - http://mdc.sagepub.com/content/15/28/15.short
4100  - http://mdc.sagepub.com/content/15/28/15.full
AB  - TECOS was a large randomized placebo-controlled trial in patients with type 2 diabetes mellitus and cardiovascular disease, conducted to demonstrate the noninferiority of sitagliptin as compared with placebo in the risk of cardiovascular events. A prespecified secondary analysis found no impact of sitagliptin on heart failure hospitalization or related events.